메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Everest Medicines Announces Participation in September In…

SHANGHAI, Aug. 25, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer will be participating in person at investor conferences in New York City. Morgan Stanley 23rd Annual Global Healthcare Conference Date: Monday September 8, 2025 Format: Fireside chat and 1x1 meetings Time: 5:35 p.m. ET Location: New York, NY&nbs
- 김갑성 기자
- 2025-08-25 20:57
Peijia Medical Announces 2025 Interim Results

HONG KONG, Aug. 25, 2025 -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025. The Group reported sustained revenue growth and significantly improved expense ratios, driving a structural enhancement in profitability. Revenue reached RMB353.4 million, up 17.3% period-to-period. Revenue composition remained stable, with TAVR-related products and
- 김갑성 기자
- 2025-08-25 20:00
Acceleration in Clinical Development! Leads Biolabs' LBL-03…

NANJING, China, Aug. 25, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data. This milestone endows LBL-034 with the potential to become the first domestic T-cell engager (TCE) therapy targeting GPRC5D. Innovative Design with Best-in-Class Potential LBL-034 is a GPRC5D/CD3 bispecific T-cell engager with a uniquely designed 2:1 format. By optimizing anti-CD3 affinity and steric
- 김갑성 기자
- 2025-08-25 18:27
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Me…

SHANGHAI, Aug. 25, 2025 -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter
- 김갑성 기자
- 2025-08-25 16:42
Lundbeck to present new data on bexicaserin at upcomin…

[ 메디채널 김갑성 기자 ] The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 DEEs are the most severe rare epilepsies, characterized by drug-resistant seizures, frequent epileptic activity on EEG and developmental slowing or regression2 Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor se
- 김갑성 기자
- 2025-08-25 15:43
Akeso Reports Phase 3 Trials Show Positive Results: Gumokim…

HONG KONG, Aug. 25, 2025 -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study successfully met all primary efficacy endpoints, including ASAS20 and subgroup analyses, as well as the key secondary endpoint ASAS40. Furthermore, several pre-specified secondary endpoints demonstrated both statistically significant and clinically meaningful improvements, further supporting th
- 김갑성 기자
- 2025-08-25 13:46
Cambrex Expands Peptide Manufacturing Capabilities in Wa…

EAST RUTHERFORD, N.J., Aug. 25, 2025 -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies. The new GMP manufacturing suite increases the overall facility footprint by 20% and includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materials and a product storage suite. Wi
- 김갑성 기자
- 2025-08-25 12:01
캠브렉스, 매사추세츠주 월섬에서 펩타이드 제조 역량 확장

이스트 러더퍼드, 뉴저지, 2025년 8월 25일 -- 글로벌 의약품 위수탁개발생산(CDMO) 선도 기업인 캠브렉스(Cambrex)가 오늘 자회사인 스냅드래곤 케미스트리(Snapdragon Chemistry)의 매사추세츠주 월섬 소재 원료의약품(API) 생산 시설을 확장하여 펩타이드 치료제 개발 및 생산 지원 역량을 더욱 강화했다고 발표했다. 새로운 GMP(Good Manufacturing Practice) 제조 라인은 전체 시설 면적을 20% 확장했으며, 정제용 HPLC 크로마토그래피 및 동결건조를 위한 ISO-7 등급 클린룸, 원자재 및 완제품 보관을 위한 저온 보관소를 포함한다. 이번 투자를 완료함으로써 스냅드래곤은 고체상 펩타이드 합성(SPPS), 액체상 펩타이드 합성(LPPS) 또는 하이브리드 접근법을 활용해 펩타이드 프로젝트의 개발부터 GMP 제조까지 지원할 수 있게 됐다. 에릭 팡(Dr. Eric Fang) 스냅드래곤 케미스트리 총괄 매니저는 "우리는 펩타이드 신약 후보 개발을 위해 3단계 전략을 염두에 두고 이 시설을 설계했다"며 "개념 증명 단계에서는 자동화된 SPPS 기술을
- 김갑성 기자
- 2025-08-25 12:01
Manulife Hong Kong and Macau Strengthens Leadership…

HONG KONG, Aug. 25, 2025 -- Manulife Hong Kong and Macau are pleased to announce three senior leadership appointments that underscore its commitment to executing strategic priorities and accelerating business growth. Danny Lee has been named Chief Health Officer, KC Cheung as Chief Product Officer, and Louisa Li as Chief Strategy Officer and Head of Macau Branch. These appointments reflect the company's sharpened focus on advancing its health proposition, driving product innovation, strengthening strategic planning, and accelerating expansion in the Macau market. Danny Lee Appointed Ch
- 김갑성 기자
- 2025-08-25 12:00
Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. In this role, Ms. Li will lead clinical development, regulatory strategy, and medical affair
- 김갑성 기자
- 2025-08-25 09:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-25_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 25일 22시 40분